Johnson & Johnson (JNJ): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Johnson & Johnson ( JNJ) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.4%. By the end of trading, Johnson & Johnson fell $0.98 (-1.1%) to $92.36 on average volume. Throughout the day, 12,114,256 shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9,866,600 shares. The stock ranged in price between $91.78-$93.39 after having opened the day at $93.39 as compared to the previous trading day's close of $93.34. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 41.8%, Tonix Pharmaceuticals ( TNXP), down 30.2%, Dendreon ( DNDN), down 26.1% and Genvec ( GNVC), down 23.2%.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $263.9 billion and is part of the health care sector. Shares are up 33.6% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, NPS Pharmaceuticals ( NPSP), up 25.4%, Geron Corporation ( GERN), up 16.4%, Aastrom Biosciences ( ASTM), up 16.3% and GW Pharmaceuticals PLC ADR ( GWPH), up 16.0% , were all gainers within the drugs industry with Theravance ( THRX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers